Disease progression in women with X-linked adrenoleukodystrophy is slow

Table 8 Generalized Linear Mixed Model subgroup analysis 2 solely including symptomatic women

	Fixed effect	B	SE	P value	95% Confidence Interval
	Fixed effect	B	SE	P value	Lower	Upper
EDSS	Baseline^	−0.107	0.040	0.010*	−0.188	−0.026
	No neurological symptoms^^	−0.347	0.109	0.002*	−0.564	−0.129
	Symptoms 10 years or shorter^^	−0.127	0.074	0.093	−0.276	0.022
ALDS	Baseline*	−0.020	0.045	0.663	−0.111	0.071
	No neurological symptoms^^	0.137	0.120	0.257	−0.103	0.377
	Symptoms 10 years or shorter^^	0.095	0.085	0.267	−0.075	0.266
	Age at examination	−0.009	0.004	0.021*	−0.016	−0.001
SF-36: PF	Baseline^	0.066	0.040	0.107	−0.015	0.146
	No neurological symptoms^^	0.352	0.131	0.010*	0.089	0.614
	Symptoms 10 years or shorter^^	0.263	0.105	0.015*	0.052	0.474
SF-36: PCS	Baseline^	0.048	0.041	0.245	−0.034	0.131
	No neurological symptoms^^	0.206	0.122	0.097	−0.038	0.450
	Symptoms 10 years or shorter^^	0.184	0.098	0.067	−0.013	0.380

Women who were symptomatic at baseline or who became symptomatic during follow-up were included (37 baseline assessments and 27 follow-up assessments). A higher EDSS score indicates higher disability. A lower ALDS score indicates higher disability. A lower physical functioning and physical component summary score indicates lower quality of life. ^ = Reference group is the follow-up visit; ^^ = Reference group is neurological symptoms > 10 years; * indicates a significant p value; ALDS = AMC Linear Disability Scale; B = coefficient; EDSS = Expanded Disability Status Scale; PCS = physical component summary; PF = physical functioning; SE = standard error; SF-36 = Short Form (36) Health Survey

ISSN: 1750-1172